Skip to main content
. 2016 Jul 22;16:107. doi: 10.1186/s12887-016-0641-7

Table 1.

Summary of patient demographics and NP-C symptomatology observed in ≥5 % of NP-C cases

NP-C cases (n = 106) NP-C non-cases (n = 31) Controls (n = 63) All patients (N = 200)
Recruitment sites, n (%)
 Brazil 16 (15) 3 (10) 13 (21) 32 (16)
 Czech Republic 6 (6) 0 (0) 6 (10) 12 (6)
 France 14 (13) 2 (6) 17 (27) 33 (17)
 Germany 19 (18) 14 (45) 0 (0) 33 (17)
 Iran 8 (8) 2 (6) 1 (2) 11 (6)
 Spain 12 (11) 10 (32) 15 (24) 37 (19)
 United Kingdom 31 (29) 0 (0) 11 (17) 42 (21)
Gender, n (%)
 Male 54 (51) 22 (71) 27 (43) 103 (52)
 Female 52(49) 9 (29) 36 (57) 97 (49)
Age (months)
 Mean (±SD) 20.8 (16.7) 29.0 (16.8) 21.9 (14.2) 22.4 (16.2)
 Median 16.5 33.0 23.0 21.5
 Minimum, maximum 0.0, 58.0 2.0, 48.0 1.0, 48.0 0.0, 58.0
Central nervous system, n (%)
Neurological symptoms
Acquired and progressive spasticity
 Yes 17 (16) 4 (13) 21 (33) 42 (21)
 No/no data 89 (84) 27 (87) 42 (67) 158 (79)
Ataxia
 Yes 34 (32) 9 (29) 21 (33) 64 (32)
 No/no data 72 (68) 22 (71) 42 (67) 136 (68)
Delayed development
Language acquisition
 Yes 41 (39) 14 (45) 32 (51) 87 (44)
 No/no data 65 (61) 17 (55) 31 (49) 113 (57)
Gross motor function
 Yes 42 (40) 18 (58) 42 (67) 102 (51)
 No/no data 64 (60) 13 (42) 21 (33) 98 (49)
Fine motor function
 Yes 32 (30) 14 (45) 34 (54) 80 (40)
 No/no data 74 (70) 17 (55) 29 (46) 120 (60)
Deterioration or loss of previously acquired physical skills
 Yes 31 (29) 6 (19) 27 (43) 64 (32)
 No/no data 75 (71) 25 (81) 36 (57) 136 (68)
Dysphagia (± dysarthria)
 Yes 21 (20) 2 (6) 22 (35) 45 (23)
 No/no data 85 (80) 29 (94) 41 (65) 155 (78)
Gelastic cataplexy
 Yes 6 (6) 0 (0) 0 (0) 6 (3)
 No/no data 100 (94) 31 (100) 63 (100) 194 (97)
Hypotonia
 Yes 46 (43) 19 (61) 39 (62) 104 (52)
 No/no data 60 (57) 12 (39) 24 (38) 96 (48)
Mental regression
 Yes 13 (12) 1 (3) 8 (13) 22 (11)
 No/no data 93 (88) 31 (97) 55 (87) 179 (90)
Urinary and faecal incontinence inappropriate to age
 Yes 13 (12) 6 (19) 13 (21) 32 (16)
 No/no data 93 (88) 25 (81) 50 (79) 168 (84)
VSGP
 Yes 14 (13) 0 (0) 5 (8) 19 (10)
 No/no data 92 (87) 31 (100) 58 (92) 181 (91)
Behavioural problems
Deterioration of previously acquired mental skills
 Yes 21 (20) 6 (19) 15 (24) 42 (21)
 No/no data 85 (80) 25 (81) 48 (76) 158 (79)
Deterioration of social interaction
 Yes 9 (8) 3 (10) 19 (30) 31 (16)
 No/no data 97 (92) 28 (90) 44 (70) 169 (85)
Visceral symptoms, n (%)
Liver signs
Hepatomegaly (historical or current)
 Yes 74 (70) 18 (58) 31 (49) 133 (62)
 No 32 (30) 13 (42) 32 (51) 77 (39)
Increased conjugated direct bilirubin levels
 Yes 44 (42) 13 (42) 11 (17) 68 (34)
 No/no data 62 (58) 18 (58) 52 (83) 132 (66)
Prolonged unexplained neonatal jaundice or cholestasis
 Yes 59 (56) 14 (45) 15 (24) 88 (44)
 No/no data 47 (44) 17 (55) 48 (76) 112 (56)
Spleen signs
Low platelet count (<150 × 109/L)
 Yes 13 (12) 10 (32) 13 (21) 36 (18)
 No 93 (88) 21 (68) 50 (79) 164 (82)
Unexplained splenomegaly (historical or current)
 Yes 83 (78) 18 (58) 23 (37) 124 (62)
 No 23 (22) 13 (42) 40 (63) 76 (38)
Pulmonary signs
Pulmonary infiltrates
 Yes 14 (13) 1 (3) 1 (2) 16 (8)
 No/no data 92 (87) 30 (97) 62 (98) 184 (92)
Pre- and peri-natal symptoms
Foetal oedema or ascites
 Yes 5 (5) 2 (6) 1 (2) 8 (4)
 No/no data 101 (95) 29 (94) 62 (98) 192 (96)
Family history, n (%)
Consanguinity of parents
 Yes 22 (21) 5 (16) 15 (24) 42 (21)
 No/no data 84 (79) 26 (84) 48 (76) 158 (79)
Parents or siblings with NP-C
 Yes 25 (24) 0 (0) 0 (0) 25 (13)
 No/no data 84 (79) 31 (100) 63 (100) 175 (89)

N, number of patients in population; n, number of patients with assessment; NP-C Niemann-Pick disease Type C, SD standard deviation, VSGP vertical supranuclear gaze palsy